EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparison of Anti-SARS-CoV-2-Specific Antibody Signatures in Maternal and Infant Blood after COVID-19 Infection versus COVID-19 Vaccination during Pregnancy

Vishakha Sabharwal iD, Elizabeth Taglauer, Riley Demos, Jennifer Snyder-Cappione, Yazdani B Shaik-Dasthagirisaheb, Samantha Parker-Kelleher, Jessica Hunnewell, Jeffery Boateng, Katherine Clarke, Rachel Yuen, Elizabeth D Barnett, Elisha M Wachman und 1 weitere

American Journal of Perinatology · 01.05.2024 · 41 (S 01 S 01) · e2970-e2977

DOI: 10.1055/a-2183-9109 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift American Journal of Perinatology, erschienen am 01.05.2024. Verfasst von Vishakha Sabharwal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Boston Medical Center, Boston, Massachusetts. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Antibodies, Viral, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, Boston University Clinical and Translational Science Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The Advisory Committee on Immunization Practices and The American College of Obstetricians and Gynecologists recommend coronavirus disease 2019 (COVID-19) vaccine for pregnant persons to prevent severe illness and death. The objective was to examine levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG, IgM, and IgA against spike protein receptor binding domain (RBD) and nucleocapsid protein (NCP) in maternal and infant/cord blood at delivery after COVID 19 vaccination compared with SARS-CoV-2 infection at in mother–infant dyads at specified time points. Study Design Mothers with SARS-CoV-2 infection (n = 31) or COVID-19 vaccination (n = 25) during pregnancy were enrolled between July 2020 and November 2021. Samples were collected at delivery and IgG, IgM, and IgA to RBD of spike and NCPs compared in the infected and vaccinated groups. Timing of infection/vaccination prior to delivery and correlation with antibody levels was performed.

Results

The majority of participants received vaccination within 90 days of delivery and over half received the Pfizer BioNTech vaccine. There were no significant correlations between antibody levels and timing of infection or vaccination. Infant IgG levels to the RBD domain of spike protein were higher in the vaccinated group (n = 25) as compared with the infants born to mothers with infection (n = 31). Vaccination against COVID-19 during pregnancy was associated with detectable maternal and infant anti-RBD IgG levels at delivery irrespective of the timing of vaccination.

Conclusion

Timing of vaccination had no correlation to the antibody levels suggesting that the timing of maternal vaccination in the cohort did not matter. There was no IgM detected in infants from vaccinated mothers. Infants from vaccinated mothers had robust IgG titers to RBD, which have a lasting protective effect in infants. Key Points

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesAntibodies, ViralSARS-CoV-2Pregnancy Complications, InfectiousImmunoglobulin GSpike Glycoprotein, CoronavirusHumansPregnancyFemaleAdultInfant, NewbornImmunoglobulin AFetal BloodImmunoglobulin MVaccinationCoronavirus Nucleocapsid Proteins

Substanzen

COVID-19 VaccinesAntibodies, ViralImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Immunoglobulin AImmunoglobulin MCoronavirus Nucleocapsid Proteins

Autor:innen und Institutionen

  • Department of Pediatrics, Boston Medical Center, Boston, Massachusetts.
  • Boston University School of Medicine, Boston, Massachusetts.
  • Department of Microbiology, Boston University School of Medicine, Boston, Massachusetts.
  • Boston University School of Public Health, Boston, Massachusetts.
  • Department of Obstetrics and Gynecology, Boston Medical Center, Boston, Massachusetts.

ORCID-Profile: Vishakha Sabharwal

Förderung

  • NCATS NIH HHS
  • Boston University Clinical and Translational Science Institute

Zitieren

APA

Sabharwal, V., Taglauer, E., Demos, R., Snyder-Cappione, J., Shaik-Dasthagirisaheb, Y. B., Parker-Kelleher, S., Hunnewell, J., Boateng, J., Clarke, K., Yuen, R., Barnett, E. D., Wachman, E. M., & Yarrington, C. D. (2024). Comparison of Anti-SARS-CoV-2-Specific Antibody Signatures in Maternal and Infant Blood after COVID-19 Infection versus COVID-19 Vaccination during Pregnancy. American Journal of Perinatology, 41(S 01 S 01), e2970-e2977. https://doi.org/10.1055/a-2183-9109

Vancouver

Sabharwal V, Taglauer E, Demos R, Snyder-Cappione J, Shaik-Dasthagirisaheb YB, Parker-Kelleher S, et al. Comparison of Anti-SARS-CoV-2-Specific Antibody Signatures in Maternal and Infant Blood after COVID-19 Infection versus COVID-19 Vaccination during Pregnancy. American Journal of Perinatology. 2024;41(S 01 S 01):e2970-e2977. doi:10.1055/a-2183-9109

BibTeX
@article{Sabharwal2024,
  author = {Sabharwal, Vishakha and Taglauer, Elizabeth and Demos, Riley and Snyder-Cappione, Jennifer and Shaik-Dasthagirisaheb, Yazdani B and Parker-Kelleher, Samantha and Hunnewell, Jessica and Boateng, Jeffery and Clarke, Katherine and Yuen, Rachel and Barnett, Elizabeth D and Wachman, Elisha M and Yarrington, Christina D},
  title = {Comparison of Anti-SARS-CoV-2-Specific Antibody Signatures in Maternal and Infant Blood after COVID-19 Infection versus COVID-19 Vaccination during Pregnancy},
  journal = {American Journal of Perinatology},
  year = {2024},
  volume = {41},
  number = {S 01 S 01},
  pages = {e2970--e2977},
  doi = {10.1055/a-2183-9109}
}
Kostenlos starten →